
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS

Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Fecha de publicación: 16 mayo de 2019 Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract Transferon®) Ver...
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody. VER MÁS
Fecha de publicación: 2 abril de 2020 Development and Evaluation of a Set of Spike and Receptor Binding Domain‐Based...
SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library VER MÁS
Characterization of a Complex Mixture of Immunomodulator Peptides Obtained from Autologous Urine. VER MÁS
Fecha de publicación: Septiembre 2019 A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced...
An international comparative analysis and roadmap to sustainable biosimilar markets. VER MÁS
Fecha de publicación: 20 Septiembre 2019 Utilization of naproxen by Amycolatopsis sp. Poz 14 and detectionof the enzymes involved...

+52 (55) 5729 6000 Ext. 62543
Escuela Nacional de Ciencias Biológicas. Prolongación de Carpio y Plan de Ayala S/N, Del. Miguel Hidalgo, CDMX, C.P. 11340.
©2026 UDIBI